Evaluate the Interest of the Pre-conceptional Endometrial Immune Profiling to Increase Birth Rates (NCT02262117) | Clinical Trial Compass
CompletedNot Applicable
Evaluate the Interest of the Pre-conceptional Endometrial Immune Profiling to Increase Birth Rates
France400 participantsStarted 2015-10-30
Plain-language summary
A prospective, randomized, controlled, open two-arm study to evaluate the interest of the pre-conceptional endometrial immune profiling to increase birth rates.
Who can participate
Age range18 Years – 38 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Infertile patients will be included at the beginning of their medical care in reproduction once the indication to perform either an IVF with or without ICSI has been established. The indication for IVF will be: tubal infertility, endometriosis, ovarian dysovulation with failure of intra-uterine insemination, idiopathic infertility The indication for ICSI will be: male infertility (oligo-astheno-teratospermia), previous failure of oocytes fertilization in IVF
* Patients should be younger than 38 years old (Age \< 38)
* with a normal ovarian reserve (AMH\>1.5ng/ml, FSH\<10 IU/l on day-3, antral follicles count (AFC) over 6 on day-3 of the cycle by ultrasound)
* The range of the IVF or ICSI attempt should be lower than 3 or equal at 2 (first or second IVF/ICSI). If a live birth occurred in the past by IVF/ICSI, the range of the new attempt is 1.
* With a signed informed and consent form
* With medical insurance
Exclusion Criteria:
* Azoospermia or cryptozoospermia (Patient's partner)
* IVF/ICSI attempt scheduled in another ART unit
* Contraindication to any experimental treatment (Cortancyl, Intralipids, Human Chorionic Gonadotropin)
* Maternal serology positive for hepatite C or B
What they're measuring
1
Live birth rate (without congenital abnormality or malformation)/transfer following the first (fresh) embryo transfer after uterine immune analysis